TD Asset Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

TD Asset Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-354	Closed	-$21K	–	1439
2020 Q1	$21K	Sell	354 -157	-31%	-$15.4K	﹤0.01%	1363
2019 Q4	$65K	Hold	511	–	–	﹤0.01%	1387
2019 Q3	$63K	Sell	511 -38	-7%	-$7.65K	﹤0.01%	1326
2019 Q2	$164K	Buy	549 +4	+0.7%	+$1.67K	﹤0.01%	1309
2019 Q1	$245K	Buy	545 +25	+5%	+$10.9K	﹤0.01%	1287
2018 Q4	$238K	Buy	520 +5	+1%	+$3.1K	﹤0.01%	1335
2018 Q3	$468K	Buy	515 +20	+4%	+$13.2K	﹤0.01%	1301
2018 Q2	$290K	Buy	495 +7	+1%	+$4.57K	﹤0.01%	1348
2018 Q1	$318K	Buy	+488	New	+$366K	﹤0.01%	1273

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kalos Management Alpharetta, Georgia $46.6M AUM 11.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TD Asset Management's HTGM Position: Q2 2020 in Review

TD Asset Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2020, closing a stake of 354 shares — an estimated $21K sold.

TD Asset Management first reported a position in HTGM in Q1 2018 and held it in 9 quarters. The position peaked at $468K in Q3 2018. 28 funds tracked by Wall St. Rank hold HTGM as of Q2 2020.

TD Asset Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
TD Asset Management sold 354 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2020, an estimated $21K.
TD Asset Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 9 quarters.
TD Asset Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $468K in Q3 2018.
28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2020.

Based on TD Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.